Literature DB >> 11682513

Evaluation of Etest method for determining posaconazole MICs for 314 clinical isolates of Candida species.

M A Pfaller1, S A Messer, K Mills, A Bolmström, R N Jones.   

Abstract

The performance of the Etest for posaconazole (SCH 56592) susceptibility testing of 314 isolates of Candida spp. was assessed against the National Committee for Clinical Laboratory Standards (NCCLS) microdilution broth method. The NCCLS method employed RPMI 1640 broth medium, and MICs were read after incubation for 48 h at 35 degrees C. MICs were determined by Etest for all 314 isolates with RPMI agar containing 2% glucose (RPG agar) and were read after incubation for 48 h at 35 degrees C. The Candida isolates included C. albicans (n = 174), C. glabrata (n = 57), C. tropicalis (n = 31), C. parapsilosis (n = 39), C. krusei (n = 5), C. guilliermondii (n = 6), and C. lusitaniae (n = 2). The Etest results correlated well with reference MICs. Overall agreement was 95%, and agreements for individual species were as follows: C. krusei, 100%; C. albicans, 98%; C. tropicalis, 97%; C. glabrata, 93%; C. parapsilosis, 85%; C. guilliermondii, 83%; and C. lusitaniae, 50%. The problem of trailing end points was minimized with RPG agar, and good agreement with broth dilution MICs was obtained when discernible growth within an established ellipse was ignored. The Etest method using RPG agar appears to be a useful method for determining posaconazole susceptibilities of Candida species.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11682513      PMCID: PMC88470          DOI: 10.1128/JCM.39.11.3952-3954.2001

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  15 in total

1.  Quality control limits for broth microdilution susceptibility tests of ten antifungal agents.

Authors:  A L Barry; M A Pfaller; S D Brown; A Espinel-Ingroff; M A Ghannoum; C Knapp; R P Rennie; J H Rex; M G Rinaldi
Journal:  J Clin Microbiol       Date:  2000-09       Impact factor: 5.948

2.  In vitro susceptibility testing of filamentous fungi: comparison of Etest and reference microdilution methods for determining itraconazole MICs.

Authors:  M A Pfaller; S A Messer; K Mills; A Bolmström
Journal:  J Clin Microbiol       Date:  2000-09       Impact factor: 5.948

3.  In vitro studies of activities of the antifungal triazoles SCH56592 and itraconazole against Candida albicans, Cryptococcus neoformans, and other pathogenic yeasts.

Authors:  J N Galgiani; M L Lewis
Journal:  Antimicrob Agents Chemother       Date:  1997-01       Impact factor: 5.191

4.  Activity of a new triazole, Sch 56592, compared with those of four other antifungal agents tested against clinical isolates of Candida spp. and Saccharomyces cerevisiae.

Authors:  M A Pfaller; S Messer; R N Jones
Journal:  Antimicrob Agents Chemother       Date:  1997-02       Impact factor: 5.191

5.  Evaluation of the Etest method for determining voriconazole susceptibilities of 312 clinical isolates of Candida species by using three different agar media.

Authors:  M A Pfaller; S A Messer; A Houston; K Mills; A Bolmstrom; R N Jones
Journal:  J Clin Microbiol       Date:  2000-10       Impact factor: 5.948

6.  In vitro activities of the new antifungal triazole SCH 56592 against common and emerging yeast pathogens.

Authors:  F Barchiesi; D Arzeni; A W Fothergill; L F Di Francesco; F Caselli; M G Rinaldi; G Scalise
Journal:  Antimicrob Agents Chemother       Date:  2000-01       Impact factor: 5.191

7.  Interlaboratory evaluation of Etest method for testing antifungal susceptibilities of pathogenic yeasts to five antifungal agents by using Casitone agar and solidified RPMI 1640 medium with 2% glucose.

Authors:  A Espinel-Ingroff; M Pfaller; M E Erwin; R N Jones
Journal:  J Clin Microbiol       Date:  1996-04       Impact factor: 5.948

8.  Evaluation of the Etest method for determining fluconazole susceptibilities of 402 clinical yeast isolates by using three different agar media.

Authors:  M A Pfaller; S A Messer; A Karlsson; A Bolmström
Journal:  J Clin Microbiol       Date:  1998-09       Impact factor: 5.948

9.  Comparison of Etest and National Committee for Clinical Laboratory Standards broth macrodilution method for antifungal susceptibility testing: enhanced ability to detect amphotericin B-resistant Candida isolates.

Authors:  A Wanger; K Mills; P W Nelson; J H Rex
Journal:  Antimicrob Agents Chemother       Date:  1995-11       Impact factor: 5.191

10.  Evaluation of the E test system versus a microtitre broth method for antifungal susceptibility testing of yeasts against fluconazole and itraconazole.

Authors:  A L Colombo; F Barchiesi; D A McGough; A W Fothergill; M G Rinaldi
Journal:  J Antimicrob Chemother       Date:  1995-07       Impact factor: 5.790

View more
  17 in total

1.  Comparison of three commercial assays and a modified disk diffusion assay with two broth microdilution reference assays for testing zygomycetes, Aspergillus spp., Candida spp., and Cryptococcus neoformans with posaconazole and amphotericin B.

Authors:  A Espinel-Ingroff
Journal:  J Clin Microbiol       Date:  2006-08-30       Impact factor: 5.948

2.  Correlation between microdilution, E-test, and disk diffusion methods for antifungal susceptibility testing of posaconazole against Candida spp.

Authors:  Charles R Sims; Victor L Paetznick; Jose R Rodriguez; Enuo Chen; Luis Ostrosky-Zeichner
Journal:  J Clin Microbiol       Date:  2006-06       Impact factor: 5.948

3.  Evaluation of disk diffusion and Etest compared to broth microdilution for antifungal susceptibility testing of posaconazole against clinical isolates of filamentous fungi.

Authors:  Shawn A Messer; Daniel J Diekema; Richard J Hollis; Linda B Boyken; Shailesh Tendolkar; Jennifer Kroeger; Michael A Pfaller
Journal:  J Clin Microbiol       Date:  2007-01-31       Impact factor: 5.948

4.  Evaluation of Etest and disk diffusion methods compared with broth microdilution antifungal susceptibility testing of clinical isolates of Candida spp. against posaconazole.

Authors:  Daniel J Diekema; Shawn A Messer; Richard J Hollis; Linda B Boyken; Shailesh Tendolkar; Jennifer Kroeger; Michael A Pfaller
Journal:  J Clin Microbiol       Date:  2007-02-14       Impact factor: 5.948

5.  Comparative evaluation of a new commercial colorimetric microdilution assay (SensiQuattro Candida EU) with MIC test strip and EUCAST broth microdilution methods for susceptibility testing of invasive Candida isolates.

Authors:  Hedda Luise Koehling; Birgit Willinger; Jan Buer; Peter-Michael Rath; Joerg Steinmann
Journal:  J Clin Microbiol       Date:  2014-11-12       Impact factor: 5.948

6.  In vitro susceptibility testing of Aspergillus spp.: comparison of Etest and reference microdilution methods for determining voriconazole and itraconazole MICs.

Authors:  J B Pfaller; S A Messer; R J Hollis; D J Diekema; M A Pfaller
Journal:  J Clin Microbiol       Date:  2003-03       Impact factor: 5.948

7.  Evaluation of Etest method for determining fluconazole and voriconazole MICs for 279 clinical isolates of Candida species infrequently isolated from blood.

Authors:  M J Maxwell; S A Messer; R J Hollis; L Boyken; S Tendolkar; D J Diekema; M A Pfaller
Journal:  J Clin Microbiol       Date:  2003-03       Impact factor: 5.948

8.  E-test method for testing susceptibilities of Aspergillus spp. to the new triazoles voriconazole and posaconazole and to established antifungal agents: comparison with NCCLS broth microdilution method.

Authors:  Ana Espinel-Ingroff; A Rezusta
Journal:  J Clin Microbiol       Date:  2002-06       Impact factor: 5.948

9.  Caspofungin Etest endpoint for Aspergillus isolates shows poor agreement with the reference minimum effective concentration.

Authors:  Jeff Fuller; Adam Schofield; Safeer Jiwa; Crystal Sand; Brad Jansen; Robert Rennie
Journal:  J Clin Microbiol       Date:  2009-12-09       Impact factor: 5.948

10.  Evaluating the resistance to posaconazole by E-test and CLSI broth microdilution methodologies of Candida spp. and pathogenic moulds.

Authors:  R Araujo; S Costa-de-Oliveira; I Coutinho; A G Rodrigues; C Pina-Vaz
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2009-04-07       Impact factor: 3.267

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.